Antibiotic Treatment for Gram-Positive Bacilli Infections

Primary Antibiotic Coverage

Vancomycin is the first-line antibiotic for serious gram-positive bacilli infections, particularly for organisms like Bacillus species and Corynebacterium jeikeium, which are susceptible only to vancomycin, as recommended by the Infectious Diseases Society of America 1
The American College of Clinical Pharmacy recommends vancomycin dosing of 30-60 mg/kg/day in divided doses, targeting trough concentrations of 15-20 mcg/mL for severe infections 2
The Infectious Diseases Society of America suggests that carbapenems (imipenem, meropenem) have excellent activity against most gram-positive bacilli strains, including many that are penicillin-resistant 1
Piperacillin-tazobactam provides broad coverage, including gram-positive organisms (except MRSA), and can be used in renal impairment with dose adjustment, according to the Infectious Diseases Society of America 1

The National Kidney Foundation recommends that vancomycin requires dose adjustment and therapeutic drug monitoring to achieve optimal concentrations while minimizing nephrotoxicity in patients with impaired renal function 1
The American College of Clinical Pharmacy suggests that daily renal function assessment is required in patients with shock, and therapeutic drug monitoring for vancomycin (target trough 15-20 mcg/mL) is essential 3

The Infectious Diseases Society of America recommends daptomycin as an alternative agent for gram-positive bacilli in cases of higher risk for nephrotoxicity or in settings with high prevalence of vancomycin-resistant strains 4
The American College of Clinical Pharmacy suggests that linezolid is not recommended for empirical use but can be used for confirmed resistant gram-positive infections 4

The Infectious Diseases Society of America recommends that vancomycin should be incorporated into initial empiric regimens for high-risk patients with clinically suspected serious catheter-related infections, known colonization with penicillin- and cephalosporin-resistant pneumococci or methicillin-resistant S. aureus, positive blood culture for gram-positive bacteria before final identification, or hypotension or cardiovascular compromise 1
The Society of Critical Care Medicine suggests that vancomycin should be discontinued 24-48 hours later if no resistant gram-positive infection is identified 1
The Infectious Diseases Society of America recommends that for patients with antibiotic resistance history, empiric broad-spectrum coverage should include vancomycin plus an anti-gram-negative agent (fourth-generation cephalosporin, carbapenem, or beta-lactam/beta-lactamase combination) 4